Adcock turns focus from survival to development

After being in “remedial mode” for the past two years, JSE-listed pharmaceuticals giant Adcock Ingram is eyeing growth and development after generating healthy amounts of cash and accumulating “significant” resources during the year ended June 30. The group, which is progressing the sale of its lossmaking India assets, now aims to pursue its nonregulated product portfolio expansion plans through partnerships and acquisitions.